Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INVIVYD, INC. via INVIVYD, INC.
2023 · fourth_quarter · Q4
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
education and awareness of COVID-19 therapeutics
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
Source: Senate LDA
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Preparing for All Hazards and Pathogens Reauthorization Act
Client: INVIVYD, INC. · Firm: INVIVYD, INC.
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Preparing for All Hazards and Pathogens Reauthorization Act
Client: INVIVYD, INC. · Firm: INVIVYD, INC.
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Preparing for All Hazards and Pathogens Reauthorization Act
Client: INVIVYD, INC. · Firm: INVIVYD, INC.
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
INVIVYD, INC. via INVIVYD, INC.
2023 · first_quarter · Q1
education and awareness of COVID-19 therapeutics
education and awareness of COVID-19 therapeutics
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
INVIVYD, INC. via INVIVYD, INC.
2023 · third_quarter · Q3
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
education and awareness of COVID-19 therapeutics
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
INVIVYD, INC. via INVIVYD, INC.
2023 · second_quarter · Q2
education and awareness of COVID-19 therapeutics
education and awareness of COVID-19 therapeutics issues related to H.R. 3832 - The Disease X Act of 2023, and H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
INVIVYD, INC. via INVIVYD, INC.
2023 · first_quarter · Q1
education and awareness of COVID-19 therapeutics
education and awareness of COVID-19 therapeutics
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
INVIVYD, INC. via INVIVYD, INC.
2022 · fourth_quarter · Q4
Education and awareness related to COVID-19 therapeutics
Education and awareness related to COVID-19 therapeutics
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
INVIVYD, INC. via INVIVYD, INC.
2022 · third_quarter · Q3
Education and awareness related to COVID-19 therapeutics
Education and awareness related to COVID-19 therapeutics
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
INVIVYD, INC. via INVIVYD, INC.
2022 · second_quarter · RA
Education and awareness related to COVID-19 therapeutics
Education and awareness related to COVID-19 therapeutics
INVIVYD, INC. via INVIVYD, INC.
2022 · second_quarter · Q2
Education and awareness related to COVID-19 therapeutics
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INVIVYD, INC. via INVIVYD, INC.
2022 · second_quarter · RR
education and awareness related to COVID-19 therapeutics
education and awareness related to COVID-19 therapeutics